PKPınar Korkmaz

Pınar Korkmaz

*This is an algorithmically generated author record based on publicly available information.

Pınar Korkmaz has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Granulomatous Mastitis, Erythema Nodosum, and Arthritis Syndrome: Case Presentation and Literature Review

    by Fatih Albayrak, Orhan Zengin, Reha Baran, Pınar Korkmaz, Hüseyin Çolak, Erdem Taş

    Granulomatous mastitis (GM) is an inflammatory breast disease that may rarely be accompanied by systemic manifestations such as erythema nodosum (EN) and arthritis. In recent years, the association of GM with EN, with or without arthritis, has been recognized as GMENA syndrome. This report presents a case of GMENA syndrome and reviews the published literature. A 26-year-old woman presented with swelling, erythema, pain, and discharge in the left breast. Initial evaluation suggested infectious mastitis, but prolonged antibiotic therapy was ineffective. During follow-up, bilateral ankle arthritis and pretibial EN developed. Laboratory tests showed marked systemic inflammation. Core needle biopsy demonstrated chronic granulomatous inflammation, and microbiological studies were negative. The GMENA syndrome was diagnosed after exclusion of alternative causes. Methylprednisolone led to rapid improvement in both breast and systemic manifestations. A review of published cases showed a similar pattern of unilateral breast involvement, EN, and frequent peripheral arthritis or arthralgia, with generally favorable responses to corticosteroid therapy. Granulomatous mastitis should be considered in patients with treatment-resistant inflammatory breast lesions accompanied by systemic findings such as EN and arthritis. Recognition of this clinical pattern may help avoid unnecessary antibiotic use and allow timely initiation of appropriate immunosuppressive treatment.

  • Open Access

    Effects of Omalizumab on Serum Levels of Substance P, Calcitonin Gene-Related Peptide, Neuropeptide Y, and Interleukin-31 in Patients with Chronic Spontaneous Urticaria

    by Cagdas Boyvadoglu, Hasan Ulusal, Seyithan Taysı, Goknur Ozaydin-Yavuz, Ibrahim Halil Yavuz, Pınar Korkmaz, Huseyin Serhat Inaloz

    The mechanism of action of omalizumab in urticaria is still not literally known. This study examines the serum values of substance P (SP), calcitonin gene-related peptide (CGRP), neuropeptide Y (NPY), and interleukin-31 (IL-31) in patients using omalizumab. In this study, 30 patients with chronic spontaneous urticaria (CSU) who were going to be treated with omalizumab and 20 healthy volunteers took part. Demographic data, clinical data, and disease activity scores were noted. For serum SP, CGRP, NPY, and IL-31 values, 10 mL of blood were taken from the patients before starting the treatment, 3 months after the treatment, at the end of the 6th month, and from healthy volunteers all at once. The change in values measured at baseline, 3rd month, and 6th month was analyzed by the Friedman Test. The Mann–Whitney U test was used to compare the parameters obtained from the patients and control groups. The significance level was set at . SP, CGRP, NPY, and IL-31 values were all statistically significantly lower in the CSU patient group compared to the control group. After treatment, the levels of SP and CGRP in the serum went up, and the levels of serum IL-31 went down. These changes were statistically significant. This study supports the view that omalizumab does not only affect IgE receptors but also affects mast cells through other mechanisms. According to our knowledge, this is the first study to show that omalizumab therapy and serum CGRP levels are related.


  • Mortaliteyle Sonuçlanan Geç Başlangıçlı Warfarin Kaynaklı Cilt Nekrozu Olgusu

    by Sinem Bayrakçi, Pınar Korkmaz

    Warfarin-induced skin necrosis is a rare complication of warfarin therapy and is associated with high mortality. Here, we present a case of warfarin-induced skin necrosis, that was fatal in a 53-year-old female patient who was started on warfarin treatment 5.5 years ago due to atrial fibrillation and previous mitral valve surgery. Patients using warfarin should be evaluated for warfarin-induced skin necrosis when they present with skin lesions. Early diagnosis, early discontinuation of the drug, early initiation of supportive treatment can be life-saving.